Morgan Stanley: Maintains "overweight" rating on PICC Group (01339) with a target price of HK$7.6.
The bear market scenario valuation has been adjusted upward by 2.4% to 4.2 Hong Kong dollars due to an increase in shareholder equity, while the bull market scenario valuation has been adjusted downward by 7.2% to 14.1 Hong Kong dollars due to a slight slowdown in intrinsic value growth, changes based on assumptions of the company's long-term investment return may result in a slowdown in expected returns.
Morgan Stanley has released a research report stating that, according to the updated model of PICC GROUP (01339) based on the first half performance, the forecast for per share earnings of Ping An Insurance has been raised by 0.3% to 4.3% for each year from 2021 to 2027. The bank maintains its unchanged benchmark valuation for Ping An Insurance, with a target price of 7.6 Hong Kong dollars and a "buy" rating. In the bear market scenario, the valuation is adjusted by an increase of 2.4% to 4.2 Hong Kong dollars due to an increase in shareholders' equity, while in the bull market scenario, the valuation is slightly reduced by 7.2% to 14.1 Hong Kong dollars as the growth in intrinsic value has slowed down, and the change in assumptions about long-term investment returns of the company may lead to a slowdown in expected returns.
Related Articles

Shanghai Fosun Pharmaceutical (600196.SH): Two injectable products of Denosumab have received approval for registration in the European Union.

Gansu Longshenrongfa Pharmaceutical Industry(300534.SZ): Tongmai Oral Liquid Approved for Listing and Sales

Bank of Nanjing (601009.SH) received an additional investment of 0.99% of its shareholding from shareholder Nanjing Gaoke.
Shanghai Fosun Pharmaceutical (600196.SH): Two injectable products of Denosumab have received approval for registration in the European Union.

Gansu Longshenrongfa Pharmaceutical Industry(300534.SZ): Tongmai Oral Liquid Approved for Listing and Sales

Bank of Nanjing (601009.SH) received an additional investment of 0.99% of its shareholding from shareholder Nanjing Gaoke.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025